PT - JOURNAL ARTICLE AU - Ogungbe, Oluwabunmi AU - Jabakhanji, Samira Barbara AU - Mehta, Roopa AU - McCaffrey, John AU - Byrne, David AU - Hurley, Sinéad AU - Rosman, Lori AU - Bansah, Eyram Cyril AU - Ibukun, Folahan AU - Quarshie, Irene Afua AU - Lord, Katherine AU - Lu, Yidan AU - Wang, Yunzhi AU - Rayani, Asma AU - Liu, Hairong AU - Joseph, Ann AU - Escobosa, Alejandro AU - Nyamuame, Ivy AU - Lee, Jieun AU - Meng, Ning AU - Jehanzeb, Ibrahim AU - Akinyemi, Temitope AU - Nohara, Shoichiro AU - Mediano, Mauro F. F. AU - Yeboah-Kordieh, Yvette AU - de Sousa, Cecilia AU - Farhat, Juliana AU - de Mello, Renato Bandeira AU - Taeed, Tara AU - Appel, Lawrence J. AU - Angell, Sonia Y. AU - Gregg, Edward W. AU - Matsushita, Kunihiro TI - Disruption to diabetes and hypertension care during the COVID-19 pandemic in Latin America and the Caribbean and mitigation approaches: A Scoping Review AID - 10.1101/2024.04.17.24305997 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.17.24305997 4099 - http://medrxiv.org/content/early/2024/04/19/2024.04.17.24305997.short 4100 - http://medrxiv.org/content/early/2024/04/19/2024.04.17.24305997.full AB - Background The COVID-19 pandemic disrupted care for non-communicable diseases globally. This study synthesizes evidence on disruptions to primary care, focusing on hypertension and diabetes care and mitigation approaches taken during the pandemic in Latin America and the Caribbean (LAC).Methods We conducted a scoping review, searching nine electronic databases for studies from January 2020 to December 2022 on COVID-19-related primary care disruptions and interventions, including studies on hospital-based interventions given their relevance to the pandemic response in LAC. We adapted the Primary Health Care Performance Initiative framework to develop our search strategy and synthesize data. For studies reporting interventions, we included studies conducted outside of LAC.Findings Of 33,510 references screened, 388 studies were included (259 reported disruptions in LAC, 61 interventions in LAC, 63 interventions outside LAC, and five interventions from countries within and outside LAC), with three-quarters presenting data from Brazil, Argentina, Mexico, and Peru; few studies focused on rural areas. Additionally, the few studies that adequately quantified care disruptions reported a reduction in hypertension and diabetes control during the pandemic (e.g., hypertension control rate decreased from 68% to 55% in Mexico). Frequently reported causes of disruption included burnout and mental health challenges among healthcare workers (with disproportionate effects by type of worker), reduced medication supplies, and reduced frequency of clinic visits by patients (e.g., due to financial constraints). The most reported interventions included remote care strategies (e.g., smartphone applications, virtual meeting platforms) and mental health programs for healthcare workers. Remote care strategies were deemed feasible for care delivery, triaging, and clinical support for non-physicians. Patients were generally satisfied with telemedicine, whereas providers had mixed perceptions. Robust evidence on the effectiveness of remote care strategies for diabetes and hypertension care was unavailable in LAC.Interpretation Hypertension and diabetes control appeared to worsen in LAC during the pandemic. Major reported causes of care disruptions were workforce issues, reduced medication supply, and changes in patient perceptions of seeking and receiving primary healthcare. Remote care strategies were feasible for various purposes and were well received by patients. However, the lack of data on intervention effectiveness underscores the importance of strengthening research capacity to generate robust evidence during future pandemics. Developing resilient healthcare systems able to provide care for hypertension and diabetes during future pandemics will depend on investment in the healthcare workforce, medical supply chain, health data and research infrastructure, and technology readiness.Funding This work was supported by funding from the World Bank to Johns Hopkins Bloomberg School of Public Health and RCSI University of Medicine and Health Sciences. Additional support to RCSI was provided by Science Foundation Ireland, Converge Programme, grant number 22/RP/10091.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/38262656/ Funding StatementThis work was supported by funding from the World Bank to Johns Hopkins Bloomberg School of Public Health and RCSI University of Medicine and Health Sciences. Additional support to RCSI was provided by Science Foundation Ireland, Converge Programme, grant number 22/RP/10091.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.